2024
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt B, Kendra K, Lea J, Lee N, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington S, Wyse E, Zanotti K, McMillian N, Espinosa S. Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 117-135. PMID: 38503056, DOI: 10.6004/jnccn.2024.0013.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesVulvar cancerClinical practice guidelinesCell carcinomaHistologically squamous cell carcinomaSystemic therapy optionsSquamous cell carcinomaBasal cell carcinomaExtramammary Paget's diseasePractice guidelinesVerrucous carcinomaGynecologic malignanciesHuman papillomavirusVulvar neoplasiaTherapy optionsPaget's diseaseInflammatory conditionsRisk factorsCigarette smokingCarcinomaCancerIncreasing ageHistologyNCCNVulvar
2023
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt B, Lea J, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Aggarwal S, Espinosa S. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. Journal Of The National Comprehensive Cancer Network 2023, 21: 1224-1233. PMID: 38081139, DOI: 10.6004/jnccn.2023.0062.Peer-Reviewed Original ResearchConceptsCervical cancerNCCN guidelinesNCCN Guidelines InsightsSystemic therapy recommendationsAdvanced cervical cancerMetastatic diseaseTreatment landscapeClinical outcomesDiagnostic workupHistopathologic classificationTherapy recommendationsCancerMolecular profileAspects of managementRecent updatesDiagnostic featuresGuidelinesWorkupStagingDiseaseRecurrentPathologyRecent Key Studies in Cancers of the Uterine Corpus and Cervix: New Updates in Immunotherapy, the Microbiome, Bone Density, Quantifying Lymphovascular Invasion, and Hypofractionated Pelvic Radiation Therapy.
Harkenrider M, Fields E, Chopra S, Damast S, Kidd E, Chino J. Recent Key Studies in Cancers of the Uterine Corpus and Cervix: New Updates in Immunotherapy, the Microbiome, Bone Density, Quantifying Lymphovascular Invasion, and Hypofractionated Pelvic Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 115: 269-275. PMID: 36621226, DOI: 10.1016/j.ijrobp.2022.07.1833.Peer-Reviewed Original ResearchUterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Chu C, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Giuntoli R, Han E, Holmes J, Howitt B, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington S, Wyse E, Zanotti K, McMillian N, Aggarwal S. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 181-209. PMID: 36791750, DOI: 10.6004/jnccn.2023.0006.Peer-Reviewed Original ResearchConceptsUterine neoplasmsNCCN guidelinesNCCN Clinical Practice GuidelinesPure endometrioid carcinomasUterine cancer casesClinical practice guidelinesFemale genital tractMesenchymal sarcomaEndometrial histologyEndometrioid cancerCommon malignancyEndometrial carcinomaUncommon subtypeEndometrioid carcinomaUterine cancerGenital tractCancer casesPractice guidelinesCarcinomaNeoplasmsCancerGuidelinesAdenocarcinomaEndometriumSarcomaThe Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma
Patrich T, Wang Y, Elshaikh M, Zhu S, Damast S, Li J, Fields E, Beriwal S, Keller A, Kidd E, Usoz M, Jolly S, Jaworski E, Leung E, Taunk N, Chino J, Russo A, Lea J, Lee L, Albuquerque K, Hathout L. The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma. American Journal Of Clinical Oncology 2023, 46: 114-120. PMID: 36625449, DOI: 10.1097/coc.0000000000000975.Peer-Reviewed Original ResearchConceptsStage IIIC endometrial carcinomaRecurrence-free survivalNon-black patientsParaaortic lymph nodesGrade 3 tumorsBlack patientsOverall survivalEndometrial carcinomaWorse OSLymph nodesNonendometrioid histologyPositive paraaortic lymph nodesRetrospective multi-institutional studyKaplan-Meier methodMulti-institutional studySPSS version 27Adjuvant chemotherapyConcurrent chemoradiotherapyHazard ratioRFS ratesClinical outcomesRandomized trialsNonsignificant trendPatientsPrognostic covariates
2022
Brachytherapy impacts on sexual function: An integrative review of the literature focusing on cervical cancer
Chin C, Damast S. Brachytherapy impacts on sexual function: An integrative review of the literature focusing on cervical cancer. Brachytherapy 2022, 22: 30-46. PMID: 36567175, DOI: 10.1016/j.brachy.2022.10.012.Peer-Reviewed Original ResearchConceptsSexual morbidityCervical cancerSexual sequelaeImage-guided adaptive brachytherapyQuality of lifeSecondary preventionCurative treatmentDosimetric factorsCommon symptomsVaginal doseCancer patientsClose surveillanceSexual functionIndirect sequelaeSexual symptomsVaginal morbidityVaginal toxicitySexual dysfunctionAdaptive brachytherapySexual healthClinical interventionsMorbidityCritical organsSequelaeEffect relationshipImplementing a simulation-based curriculum for hybrid intracavitary/interstitial brachytherapy using a new, commercially available, US/MR/CT-compatible gynecologic phantom
Li J, Tien C, Kassick M, Peters G, Damast S. Implementing a simulation-based curriculum for hybrid intracavitary/interstitial brachytherapy using a new, commercially available, US/MR/CT-compatible gynecologic phantom. Brachytherapy 2022, 22: 157-165. PMID: 36528476, DOI: 10.1016/j.brachy.2022.11.006.Peer-Reviewed Original ResearchRadiation therapy in the definitive management of medically inoperable endometrial cancer
Chin C, Damast S. Radiation therapy in the definitive management of medically inoperable endometrial cancer. International Journal Of Gynecological Cancer 2022, 32: 323-331. PMID: 35256419, DOI: 10.1136/ijgc-2021-002532.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingInoperable patientsEndometrial cancerImage-guided brachytherapyRadiation therapySystemic anti-tumor immune responseAnti-tumor immune responseThree-dimensional image-guided brachytherapyInoperable endometrial cancerDefinitive radiation therapyPoor surgical candidatesNovel systemic agentsRecent consensus guidelinesHigh-volume centersExtent of tumorRates of obesityMagnetic resonance imagingMedical inoperabilityLate morbiditySurgical candidatesSystemic agentsClinical stagingDefinitive managementOngoing trialsUterine sizeAn evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva
Li JY, Arkfeld CK, Tymon-Rosario J, Webster E, Schwartz P, Damast S, Menderes G. An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva. Journal Of Gynecologic Oncology 2022, 33: 0. PMID: 34910394, PMCID: PMC8899873, DOI: 10.3802/jgo.2022.33.e13.Peer-Reviewed Original ResearchConceptsDisease-specific survivalSquamous cell carcinomaOverall survivalPositive marginsCell carcinomaNodal involvementPrognostic factorsStage IFive-year disease-specific survivalPrimary squamous cell carcinomaRecurrent squamous cell carcinomaFive-year RFSNode-positive patientsVulvar cancer patientsEscalation of treatmentConservative surgical approachKaplan-Meier estimatesLog-rank testCox proportional hazardsLocal RFSOverall RFSAdjuvant radiotherapyDistant recurrenceFree survivalMedian survivalImproving Radiation Therapy for Cervical Cancer
Kidd E, Harkenrider M, Damast S, Fields E, Chopra S, Chino J. Improving Radiation Therapy for Cervical Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: 841-848. PMID: 35190051, DOI: 10.1016/j.ijrobp.2021.12.006.Peer-Reviewed Original ResearchSecondary Prevention, Not Secondary Importance: Embracing Survivorship Concerns and HRT After Cervical Cancer Radiation Therapy
Damast S, Chino J. Secondary Prevention, Not Secondary Importance: Embracing Survivorship Concerns and HRT After Cervical Cancer Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: 414-416. PMID: 34998535, DOI: 10.1016/j.ijrobp.2021.09.028.Peer-Reviewed Original ResearchDosimetric study of Varian Universal Multi-Channel Cylinder System for High-Dose-Rate 192Ir Brachytherapy
Tien CJ, Damast S, Chen ZJ. Dosimetric study of Varian Universal Multi-Channel Cylinder System for High-Dose-Rate 192Ir Brachytherapy. Brachytherapy 2022, 21: 244-254. PMID: 34996715, DOI: 10.1016/j.brachy.2021.11.001.Peer-Reviewed Original Research
2021
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.Peer-Reviewed Original ResearchConceptsObjective response rateImmune checkpoint inhibitorsProgression-free survivalEndometrial cancerWhole-exome sequencingSporadic endometrial cancerOverall survivalEnd pointPhase 2 pilot studyPrimary end pointSecondary end pointsTumor mutation burdenPhase 2 evaluationLarger confirmatory studiesAntigen processing/presentationProcessing/presentationCheckpoint inhibitorsSurgical resectionICI resistanceDMMR patientsPrognostic significanceDMMR tumorsMechanisms of resistanceLocal treatmentSporadic MSIDoes Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma?
Yoon J, Fitzgerald H, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ, Hathout L. Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma? Practical Radiation Oncology 2021, 12: e123-e134. PMID: 34822999, DOI: 10.1016/j.prro.2021.10.002.Peer-Reviewed Original ResearchConceptsStage IIIC1 endometrial cancerPelvic radiation therapyOverall survivalEndometrial cancerRadiation therapySurvival outcomesFirst recurrenceHazard ratioRFS ratesCommon siteRecurrence-free survival ratesMulti-institutional retrospective studyPropensity scoreCox proportional hazards modelImproved survival outcomesKaplan-Meier methodProportional hazards modelInternational FederationNew therapeutic approachesAdjuvant chemotherapyDistant recurrenceSystemic chemotherapyImprove OutcomesClinical outcomesDistant metastasisPrognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalEndometrioid endometrial cancerVaginal brachytherapyPMMR patientsOverall survivalEEC patientsEndometrial cancerExact testThree-year recurrence-free survivalEarly-stage endometrial cancerCox proportional hazards regressionPoor recurrence-free survivalAdjuvant vaginal brachytherapyThree-year OSMultivariable Cox regressionLympho-vascular invasionSignificant prognostic variablesProportional hazards regressionLog-rank testKaplan-Meier estimatesDeficient mismatch repairMismatch repair statusFisher's exact testMismatch repair deficiencyDMMR statusReports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical Cancer
Damast S, Fields E, Kidd E, Harkenrider M, Chopra S, Chino J. Reports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 299-306. PMID: 34473967, DOI: 10.1016/j.ijrobp.2021.05.002.Peer-Reviewed Original ResearchNCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.
Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 888-895. PMID: 34416706, DOI: 10.6004/jnccn.2021.0038.Peer-Reviewed Original ResearchRadiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.Peer-Reviewed Original ResearchA phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.Commentaries, Editorials and LettersA Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer
Hathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 110: 1423-1431. PMID: 33677053, DOI: 10.1016/j.ijrobp.2021.02.055.Peer-Reviewed Original ResearchConceptsStage IIIC endometrial carcinomaOverall survivalEndometrial carcinomaRadiation therapyAdjuvant chemotherapyAdjuvant therapyPALN recurrenceSystemic chemotherapyRFS ratesMulti-institutional retrospective cohort studyStage IIIC endometrial cancerRecurrence-free survival ratesLymph node recurrenceSequential radiation therapyAdjuvant radiation therapyRetrospective cohort studyGrade 3 tumorsAdjuvant treatment regimensKaplan-Meier methodVaginal cuff brachytherapyHigh rateSequence of treatmentChemotherapy concurrentNodal radiationNode recurrence